

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number	10/699,874
	Filing Date	2003-11-03
	First Named Inventor	Arthur KUNZ
	Art Unit	1642
	Examiner Name	Brandon FETTEROLF
	Attorney Docket Number	P194 1011.1

U.S. PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code [†]	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5,714,586 (equivalent to WO 96/40261)		1998-02-03	American Cyanamid	
	2	7,355,011 (equivalent to WO 03/093320)		2008-04-08	UCB Pharma S.A	
	3	5,714,350		1998-02-03	Co	
	4	5,686,072		1997-11-11	Uhr	
	5	5,693,762		1997-12-02	Queen	
	6	6,183,744 (equivalent to WO 98/56418)		2001-02-06	Immunomedics, Inc.	
	7	5,382,510 (equivalent to WO 92/00311)		1995-01-17	The Trustees of Princeton University	
	8	7,541,034 (equivalent to WO 98/041641)		2009-06-02	The United States of America as represented by the Department of Health and Human Services	
	9	7,012,135 (equivalent to WO 01/94585)		2006-03-14	Celltech Chiroscience Limited	
	10	5,558,864 (equivalent to WO 92/15683)		1996-09-24	Merck Patent Gesellschaft Mit Beschränker Haftung	
	11	6,180,377 (equivalent to WO 94/29451)		2001-01-30	Celltech Therapeutics Limited	
	12	7,115,723 (equivalent to WO 00/31141)		2006-10-03	Korea Institute of Science & Technology	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>		Application Number	10/699,874
		Filing Date	2003-11-03
		First Named Inventor	Arthur KUNZ
		Art Unit	1642
		Examiner Name	Brandon FETTEROLF
		Attorney Docket Number	P194 1011.1

	13	5,225,539 (equivalent to EP 0239400)		1993-07-06	Medical Research Council	
	14	5,530,101 (equivalent to WO 90/07861)		1996-06-25	Protein Design Labs, Inc.	
	15	5,436,265 (equivalent to RU 2131423)		1995-07-25	Merck Frosst Canada, Inc.	
	16	7,129,053 (equivalent to WO 01/027612)		2006-10-31	Reiter	
	17	7,147,851 (equivalent to WO 98/006248)		2006-12-12	Ponath	
	18	6,777,390 (equivalent to WO 99/066031)		2004-08-17	Matthiessen	
	19	5,789,554 (equivalent to WO 96/004925)		1998-08-04	Leung	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	2006/0073137 (equivalent to WO 91/09967)		2006-04-06	Celltech R&D Limited	
	2	2002/0141990 (equivalent to WO 98/19704)		2002-10-03	SmithKline Beecham Corp	
	3	2007/0172920 (equivalent to JP 10-505231)		2007-02-22	Leung	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number	10/699,874
		Filing Date	2003-11-03
		First Named Inventor	Arthur KUNZ
		Art Unit	1642
		Examiner Name	Brandon FETTEROLF
		Attorney Docket Number	P194 1011.1

	4	2005/0095238 (equivalent to WO 01/078779)		2005-05-05	Brettman	
--	---	-------------------------------------------------	--	------------	----------	--

If you wish to add additional U.S. Published Application citation information please click the Add button

FOREIGN PATENT DOCUMENTS						
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document
	1	96/005306 (equivalent to RU 9710420 A)	WO		1996-02-22	Myriad Genetics, Inc.
	2	98/56418	WO		1998-12-17	Genetech, Inc.

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.
	1	Benhar et al., "Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization," <i>Bioconjugate Chem.</i> , 1994, 5: 321-326. (Abstract only) <input type="checkbox"/>
	2	Browning et al., "B cells move to centre stage: novel opportunities for autoimmune disease treatment," <i>Nat. Rev. Drug Discov.</i> , 2006, 5: 564-576. <input type="checkbox"/>
	3	Carnahan et al., "Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties," <i>Clinical Cancer Res.</i> , 2003, 9, suppl.: 3982s-3990s. <input type="checkbox"/>
	4	DiJoseph et al., "Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22," <i>Cancer Immunol. Immunother.</i> , 2005, 54: 11-24. <input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10/699,874
	Filing Date	2003-11-03
	First Named Inventor	Arthur KUNZ
	Art Unit	1642
	Examiner Name	Brandon FETTEROLF
	Attorney Docket Number	P194 1011.1

5	DiJoseph et al., "Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies," <i>Blood</i> , 2004, 103: 1807-1814.
6	Leung et al., "Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2," <i>Mol. Immunol.</i> , 1995, 32: 1413-1427. (Abstract only)
7	Leung et al., "Effect of V _k framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site," <i>Int'l. J. Cancer.</i> , 1995, 60: 534-538. (Abstract only)
8	Riechmann et al., "Reshaping human antibodies for therapy," <i>Nature</i> , 1988, 332:323-327. (Abstract only)
9	Vaughan et al., "Human antibodies by design," <i>Nature Biotech.</i> , 1998, 16: 535-539. (Abstract only)
10	van Rossenberg et al., "A structure-function study of ligand recognition by CD22 beta," <i>J. Bio. Chem.</i> , 2001, 276: 12967-12973.
11	Verhoeyen et al., "Reshaping human antibodies: Grafting an anti-lysozyme activity," <i>Science</i> , 1988, 239:1534-1536. (Abstract only)
12	Vose, J.M., "Therapeutic uses of MAbs directed against CD20" <i>Cytotherapy</i> , 2000, 2:455-461. (Abstract only)

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10/699,874
Filing Date	2003-11-03
First Named Inventor	Arthur KUNZ
Art Unit	1642
Examiner Name	Brandon FETTEROLF
Attorney Docket Number	P194 1011.1

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.